Breast cancer researcher Svasti Haricharan joins SBP faculty
A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively licensed in 2015 to a private company, DrugCendR Inc. The drug candidate was discovered in the laboratory of Erkki Ruoslahti, M.D., Ph.D., distinguished professor at SBP and founder, president and CEO of DrugCendR.
SBP and Technion Institute researchers have SHARPIN-ed their knowledge of how a malicious form of a protein drives the formation of melanoma through modulation of the PRMT5 pathway. The new research was published in The Journal of Clinical Investigation.
Scientists have identified a mechanism that explains the development of hyperaldosteronism, a condition in which the adrenal glands produce too much aldosterone, The findings, published in JCI Insight, offer a path for drug discovery to treat the condition.
Researchers have demonstrated that the drug palovarotene suppresses the formation of bony tumors (osteochondromas) in models of multiple hereditary exostoses (MHE). The research, published in the Journal of Bone and Mineral Research, is an important step toward an effective pharmacological treatment for MHE, a rare genetic condition that affects about 1 in 50,000 people worldwide.
Scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check. The study, published in Nature Communications, shows that membralin regulates the cell’s machinery for producing beta-amyloid (or amyloid beta, Aβ), the protein that causes neurons to die in Alzheimer’s disease.